Mentoring in Translational Research in Interstitial Lung Diseases

 描述(由申请人提供)：这是一项建议，旨在为德雷克博士提供有保障的时间，以便为初级临床研究人员提供更多指导，并增加她扩大间质性肺部疾病临床调查的能力。德雷克博士提出了一个指导计划，该计划将促进从初级临床研究员到研究科学家的有效过渡。她提供了她自己在临床试验实施方面的进一步培训的详细描述。她目前的研究项目通过专注于结节病临床结果的分子和免疫学决定因素来确定新的治疗干预措施，从而将主题联系在一起。特别是，她的研究重点是 分枝杆菌诱导T细胞功能障碍在结节病疾病进展中的作用，以及抗分枝杆菌治疗恢复T细胞功能的能力。受训人员参与了正在进行的以患者为导向的研究的许多方面，包括研究设计、患者收益、数据收集、实验室分析以及结果的分析和提出。研究PD-1治疗效用的提案的变革性本质是，它允许将在实验台上确定的分子机制转换为宿主内的免疫功能，并最终转换为与结节病死亡率相关的临床终点，即绝对FVC。

 DESCRIPTION (provided by applicant): This is a proposal to provide protected time for Dr. Drake to provide greater mentoring to junior clinical investigators as well as increase her capacity to expand her clinical investigations in interstitial lung disease. Dr. Drake proposes a mentoring plan which will facilitate the effective transition from junior clinical investigator to research scientist. She provides a detailed description of her own augmentation of further training in clinical trial implementation. Her current research projects are thematically linked through their focus on molecular and immunologic determinants of sarcoidosis clinical outcome for the purpose of identifying novel therapeutic interventions. In particular, her research focuses on the contribution of mycobacterial induction of T cell dysfunction to sarcoidosis disease progression, and the capacity of antimycobacterial therapy to restore T cell function. Trainees have been involved in many aspects of the ongoing patient-oriented research including study design, patient accrual, data collection, laboratory assays and analysis and presentation of findings. The transformative nature of the proposal to investigate the therapeutic utility of PD-1 is that it allows translation of molecular mechanisms identified at the bench to immune function within the host, and ultimately to a clinical endpoint associated with sarcoidosis mortality, absolute FVC.